Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Assets (2016 - 2025)

Sanofi's Non-Current Assets history spans 6 years, with the latest figure at -$45.5 billion for Q4 2024.

  • For Q4 2024, Non-Current Assets fell 37.91% year-over-year to -$45.5 billion; the TTM value through Dec 2021 reached $102.5 billion, changed N/A, while the annual FY2024 figure was -$46.1 billion, 38.94% down from the prior year.
  • Non-Current Assets for Q4 2024 was -$45.5 billion at Sanofi, down from -$33.0 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $102.5 billion in Q4 2021 and bottomed at -$45.5 billion in Q4 2024.
  • The 3-year median for Non-Current Assets is -$33.0 billion (2023), against an average of $8.0 billion.
  • The largest YoY upside for Non-Current Assets was 37.91% in 2024 against a maximum downside of 37.91% in 2024.
  • A 3-year view of Non-Current Assets shows it stood at $102.5 billion in 2021, then plummeted by 132.2% to -$33.0 billion in 2023, then crashed by 37.91% to -$45.5 billion in 2024.
  • Per Business Quant, the three most recent readings for SNY's Non-Current Assets are -$45.5 billion (Q4 2024), -$33.0 billion (Q4 2023), and $102.5 billion (Q4 2021).